These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19924252)

  • 1. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.
    Robert G; Ben Sahra I; Puissant A; Colosetti P; Belhacene N; Gounon P; Hofman P; Bost F; Cassuto JP; Auberger P
    PLoS One; 2009 Nov; 4(11):e7889. PubMed ID: 19924252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes.
    Campàs C; Lopez JM; Santidrián AF; Barragán M; Bellosillo B; Colomer D; Gil J
    Blood; 2003 May; 101(9):3674-80. PubMed ID: 12522004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
    Santidrián AF; González-Gironès DM; Iglesias-Serret D; Coll-Mulet L; Cosialls AM; de Frias M; Campàs C; González-Barca E; Alonso E; Labi V; Viollet B; Benito A; Pons G; Villunger A; Gil J
    Blood; 2010 Oct; 116(16):3023-32. PubMed ID: 20664053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
    Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P
    Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acadesine Inhibits the Proliferation of K562 Cells and Enhances their Sensitivity to Imatinib].
    Wu JJ; Wei B; Ding YH; Deng ZK; Shi YY; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):36-40. PubMed ID: 26913390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
    Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
    Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acadesine suppresses TNF-α induced complement component 3 (C3), in retinal pigment epithelial (RPE) cells.
    Efstathiou NE; Moustafa GA; Maidana DE; Konstantinou EK; Notomi S; Barbisan PRT; Georgakopoulos CD; Miller JW; Vavvas DG
    PLoS One; 2020; 15(12):e0244307. PubMed ID: 33362238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity.
    Zhu XY; Liu W; Liang HT; Tang L; Zou P; You Y; Zhu XJ
    Curr Med Sci; 2020 Oct; 40(5):871-878. PubMed ID: 33123902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells.
    Shi D; Liu Y; Xi R; Zou W; Wu L; Zhang Z; Liu Z; Qu C; Xu B; Wang X
    Int J Nanomedicine; 2016; 11():5823-5835. PubMed ID: 27853367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
    Hirao T; Yamaguchi M; Kikuya M; Chibana H; Ito K; Aoki S
    Cancer Sci; 2018 Jan; 109(1):121-131. PubMed ID: 29121435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.